Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 10,572 matching trials from the live ClinicalTrials.gov search.
Conditions
Pneumonia, Bacterial
Interventions
ME1100 inhalation solution
Drug
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Martinez, California • Sacramento, California • San Diego, California + 11 more
Conditions
Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
Interventions
Observational Protocol
Other
Lead sponsor
European Foundation for Study of Chronic Liver Failure
Other
Eligibility
18 Years to 80 Years
Enrollment
3,000 participants
Timeline
2021 – 2026
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 11 more
Conditions
Hypertension
Interventions
Firibastat, Placebo
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Huntington Beach, California • Tustin, California + 11 more
Conditions
Ewing Sarcoma, Colorectal Adenocarcinoma
Interventions
INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
12 Years to 85 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more
Conditions
Cardiovascular Disease
Interventions
Therapy Programming Report (TPR)
Behavioral
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
Not listed
Enrollment
4,384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
83
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 80 more
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
Interventions
Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
308
States / cities
Little Rock, Arkansas • Fullerton, California • Orange, California + 219 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

NCT03761914
Conditions
Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions
galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Biological · Other
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
12
States / cities
Santa Rosa, California • Whittier, California • Miami, Florida + 9 more
Conditions
Asthma
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
122
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 119 more
Conditions
Rheumatic Heart Disease in Children
Interventions
CHW Delivered SAP Adherence Supports
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Matching placebo to Seltorexant, Quetiapine XR, Matching placebo to Quetiapine XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
75
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 62 more
Conditions
Osteoporosis
Interventions
Teriparatide (PF708), Teriparatide (Forteo)
Drug
Lead sponsor
Pfenex, Inc
Industry
Eligibility
30 Years to 85 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 22 more
Conditions
Chlamydia Trachomatis, Gonorrhea
Interventions
Not listed
Lead sponsor
Hologic, Inc.
Industry
Eligibility
14 Years and older · Female only
Enrollment
1,766 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 15 more
Conditions
Angioedema
Interventions
Lanadelumab
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 12 more
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, RO4588161
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Long Beach, California + 26 more
Conditions
Influenza
Interventions
Baloxavir Marboxil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 64 Years
Enrollment
4,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 32 more
Conditions
Cardiac Disease
Interventions
DEFINITY®
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 12 more
Conditions
Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissue, High-grade Osteosarcoma
Interventions
FoundationOne Liquid CDx
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
12 Months to 50 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 9 more
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Glimepiride, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Sacramento, California + 20 more
Conditions
Diabetes, Diabetes Mellitus Type 2
Interventions
Liraglutide, Metformin, Placebo, NNC0090-2746
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
Conditions
Adenoviral Infection
Interventions
PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Burlington, Vermont
Completed Phase 4 Interventional Accepts healthy volunteers

Quetiapine in Melancholic Depression

NCT01200901
Conditions
Depression, Healthy
Interventions
Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Asthma
Interventions
AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
21
States / cities
Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

NCT00444457
Conditions
Vaccines, Pneumococcal
Interventions
13-valent Pneumococcal Conjugate Vaccine, 7vPnC
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Benton, Arkansas • Conway, Arkansas • Fayetteville, Arkansas + 67 more
Conditions
Primary Hyperoxaluria Type 1
Interventions
Not listed
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
8
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more